Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

The stock's fall snapped a two-day winning streak.

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organisations is failing to protect ...

Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...